10 results on '"Corsico, Angelo"'
Search Results
2. Mild/Moderate Asthma Network in Italy (MANI): a long-term observational study.
- Author
-
Braido, Fulvio, Blasi, Francesco, Canonica, Giorgio Walter, Paggiaro, Pierluigi, Beghè, Bianca, Bonini, Matteo, Carpagnano, Giovanna Elisiana, Del Giacco, Stefano, Lavorini, Federico, Milanese, Manlio, Patella, Vincenzo, Santus, Pierachille, Contoli, Marco, Allegrini, Chiara, Baiardini, Ilaria, Bonzano, Laura, Caiaffa, Maria Filomena, Castelnuovo, Paolo, Corsico, Angelo Guido, and Cosmi, Lorenzo
- Subjects
ASTHMA ,ASTHMATICS ,SCIENTIFIC observation ,MEDICAL research ,CLINICAL immunology ,WHEEZE - Abstract
The prevalence of asthma in Italy is estimated to be around 4%; it affects approximately 2,000,000 citizens, and up to 80–90% of patients have mild-to-moderate asthma. Despite the clinical relevance of mild-to-moderate asthma, longitudinal observational data are very limited, including data on disease progression (worsening vs. improvement), the response to treatment, and prognosis. Studies are needed to develop long-term, observational, real-life research in large cohorts. The primary outcomes of this study will be based on prospective observation and the epidemiological evolution of mild and moderate asthma. Secondary outcomes will include patient-reported outcomes, treatments over time, disease-related functional and inflammatory patterns, and environmental and life-style influences. This study, called the Mild/Moderate Asthma Network of Italy (MANI), is a research initiative launched by the Italian Respiratory Society and the Italian Society of Allergology, Asthma and Clinical Immunology. MANI is a cluster-based, real world, cross-sectional, prospective, observational cohort study that includes 20,000 patients with mild-to-moderate asthma. (ClinicalTrials.gov Identifier: NCT04796844). Despite advances in asthma care, several research gaps remain to be addressed through clinical research. This study will add important new knowledge about long-term disease history, the transferability of clinical research results to daily practice, the efficacy of currently recommended strategies, and their impact on the burden and evolution of the disease. MANI: Mild/Moderate Asthma Network of Italy SANI: Severe Asthma Network Italy GINA: Global Initiative for Asthma SABA: short acting β2-agonists ICS: inhaled corticosteroids CRF: Case Report Form [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study.
- Author
-
Radovanovic, Dejan, Contoli, Marco, Marco, Fabiano Di, Sotgiu, Giovanni, Pelaia, Girolamo, Braido, Fulvio, Corsico, Angelo Guido, Micheletto, Claudio, Rogliani, Paola, Scichilone, Nicola, Saderi, Laura, Santus, Pierachille, and Solidoro, Paolo
- Subjects
OBSTRUCTIVE lung diseases ,SEVERITY of illness index ,PULMONARY function tests ,PULMONARY emphysema ,EOSINOPHILS - Abstract
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease. The severity grading systems proposed by the Global initiative for Chronic Obstructive Lung Disease (GOLD) have changed over time. The aim of the study was to evaluate if the different GOLD classifications can capture the complexity of the disease by investigating the distribution of lung function and clinical parameters across the GOLD classification systems. This was an observational, retrospective, multicentre study. COPD patients were stratified according to the GOLD severity grading proposed in the 2007, and to the ABCD assessment tool present in the 2011, and 2017 versions of the initiative. Data from body plethysmography, DLCO, comorbidities, exacerbation history, pharmacological therapy and eosinophil counts were collected. A total of 1360 patients (73.4% males) were included in the analysis. Overall, 37% of the patients were severe-very severe according to GOLD 2007. Compared with GOLD 2011, applying the GOLD 2017 criteria, the proportion of the at risk categories (C and D) was reduced by ∼23%. Impairment in inspiratory capacity, DLCO and the prevalence of emphysema paralleled the GOLD 2007 classification only. The proportion of patients with ≥ 200 eosinophils/µL was higher in GOLD 2007 stages 3–4 compared with stages 1–2 (P = 0.008). Eosinophil levels were similar across risk classes in GOLD 2011 and 2017. Overall, 41.8% and 52.4% of the patients in the low risk groups according to GOLD 2011 and 2017 were exposed to inhaled corticosteroids. The GOLD 2011 and 2017 classifications, despite exploring symptoms and exacerbations, might miss other relevant patients' clinical characteristics such as lung function and phenotypes, which have a significant impact on outcomes and disease severity. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.
- Author
-
Contoli, Marco, Corsico, Angelo G., Santus, Pierachille, Di Marco, Fabiano, Braido, Fulvio, Rogliani, Paola, Calzetta, Luigi, and Scichilone, Nicola
- Subjects
- *
OBSTRUCTIVE lung diseases , *ADRENOCORTICAL hormones , *PRIMARY care , *DISEASE exacerbation , *MUSCARINIC antagonists , *THERAPEUTICS , *DISEASE risk factors - Abstract
Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide, whose burden is expected to increase in the next decades, because of numerous risk factors, including the aging of the population. COPD is both preventable and treatable by an effective management including risk factor reduction, prevention, assessment, and treatment of acute exacerbations and co-morbidities. The available agents approved for COPD treatment are long-acting or ultra-long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) bronchodilators, as well as inhaled corticosteroids (ICS) in combination with LABAs. ICS use has been restricted only to selected COPD patients by the most recent documents, mainly based on the risk of exacerbations. However, several observational studies showed a high rate of prescription of ICS in COPD, irrespective of clinical recommendations, questioning the efficacy of these compounds in unselected patients with COPD and leading to possible increase risk of side effects related to ICS use. After examining the low levels of adherence in primary care and in the clinical settings to national and international recommendations for the treatment of COPD in different countries, the most common drivers of the prevailing use of ICS are critically reviewed here by examining their pros and cons, aimed at identifying evidence-based drivers for a proper selection of patients who may benefit from the proper use of ICS. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
5. Advances in Identifying Urine/Serum Biomarkers in Alpha-1 Antitrypsin Deficiency for More Personalized Future Treatment Strategies.
- Author
-
Ferrarotti, Ilaria, Corsico, Angelo Guido, Stolk, Jan, Ottaviani, Stefania, Fumagalli, Marco, Janciauskiene, Sabina, and Iadarola, Paolo
- Subjects
- *
GENETIC disorder treatment , *ISOELECTRIC focusing , *ALLELES , *ALPHA 1-antitrypsin deficiency , *PATIENTS , *THERAPEUTICS - Abstract
Alpha1-antitrypsin deficiency (AATD) is a genetic disorder characterized by reduced serum levels of alpha1-antitrypsin (AAT) and increased risk for developing both early-onset lung emphysema and chronic liver disease. Laboratory diagnosis of AATD is not just a matter of degree, although the AAT serum level is the most important determinant for risk of lung damage. While being a single-gene disease, the clinical phenotype of AATD is heterogeneous. The current standard of care for patients affected by AATD-associated pulmonary emphysema is replacement therapy with weekly i.v. infusions of pooled human purified plasma AAT. Although no treatment for liver disease caused by deposition of abnormal AAT in hepatocytes is available, innovative treatments for this condition are on the horizon. This article aims to provide a critical review of the methodological steps that have marked progress in the detection of indicators described in the literature as being “clinically significant” biomarkers of the disease. The development and routine use of specific biomarkers would help both in identifying which patients and when they are eligible for treatment as well as providing additional parameters for monitoring the disease. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
6. Genuair® Usability Test: Results of a National Public Survey of the Elderly.
- Author
-
Blasi, Francesco, Canonica, Giorgio Walter, Centanni, Stefano, Mereu, Carlo, Bernabei, Roberto, Paolisso, Giuseppe, Incalzi, Raffaele Antonelli, Corsico, Angelo, Di Marco, Fabiano, Milanese, Manlio, Pagano, Francesco, Santus, Pierachille, Scichilone, Nicola, Sumberesi, Massimo, Braido, Fulvio, and Baiardini, Ilaria
- Subjects
INHALATION administration ,INHALERS ,MEDICAL care for older people ,RESPIRATORY therapy ,HEALTH outcome assessment - Abstract
Proper use of inhaler devices may be problematic in elderly patients due to age-related difficulties. A survey was administered to elderly patients to investigate the usability of the Genuair® device and patients' subjective viewpoint on the device. A representative sample of the Italian population aged ≥ 65 years was completed with a pre-defined sample of 89 patients with hand arthritis/arthrosis. Of 526 respondents, 88 were not self-sufficient. Only the replies of the 438 self-sufficient respondents were analyzed. A total of 107 participants (24%) reported having respiratory diseases, and 81 of these (76%) were users of inhaler devices. After the first test, the device was considered “practical/handy” by 90% of patients and “easy to use” by 89%. After the second test, in which patients received a demonstration of the correct inhalation maneuver, the percentage of patients scoring ≥ 7 increased to 93% for the first characteristic and was confirmed for the second, with no differences between the groups in terms of age, educational level, use of devices, and presence of arthritis/arthrosis. The mean time to explain the inhaler technique and to perform a correct inhalation was 1'38"± 1'37", and 70% of the respondents required less than 2 minutes, with no differences between the groups in terms of age, education level, use of devices, and presence of arthritis/arthrosis. In conclusion, Genuair® was well accepted and easy to use in a representative sample of the Italian population aged ≥ 65 years. These characteristics make it a valid choice in the elderly, thus enabling patients to better cope with the problems and difficulties that are common to this age group. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. The relationship between allergen immunotherapy and omalizumab for treating asthma.
- Author
-
Braido, Fulvio, Corsico, Angelo, Rogkakou, Anthi, Ronzoni, Vanessa, Baiardini, Ilaria, and Canonica, Giorgio Walter
- Published
- 2015
- Full Text
- View/download PDF
8. Oxidative Stress and Respiratory System: Pharmacological and Clinical Reappraisal of N-Acetylcysteine.
- Author
-
Santus, Pierachille, Corsico, Angelo, Solidoro, Paolo, Braido, Fulvio, Di Marco, Fabiano, and Scichilone, Nicola
- Subjects
- *
ACETYLCYSTEINE , *OXIDATIVE stress , *OBSTRUCTIVE lung diseases patients , *GLUTATHIONE peroxidase , *ANTIOXIDANTS - Abstract
The large surface area for gas exchange makes the respiratory system particularly susceptible to oxidative stress-mediated injury. Both endogenous and exogenous pro-oxidants (e.g. cigarette smoke) trigger activation of leukocytes and host defenses. These mechanisms interact in a 'multilevel cycle' responsible for the control of the oxidant/antioxidant homeostasis. Several studies have demonstrated the presence of increased oxidative stress and decreased antioxidants (e.g. reduced glutathione [GSH]) in subjects with chronic obstructive pulmonary disease (COPD), but the contribution of oxidative stress to the pathophysiology of COPD is generally only minimally discussed. The aim of this review was to provide a comprehensive overview of the role of oxidative stress in the pathogenesis of respiratory diseases, particularly COPD, and to examine the available clinical and experimental evidence on the use of the antioxidant N-acetylcysteine (NAC), a precursor of GSH, as an adjunct to standard therapy for the treatment of COPD. The proposed concept of 'multilevel cycle' helps understand the relationship between respiratory diseases and oxidative stress, thus clarifying the rationale for using NAC in COPD. Until recently, antioxidant drugs such as NAC have been regarded only as mucolytic agents. Nevertheless, several clinical trials indicate that NAC may reduce the rate of COPD exacerbations and improve small airways function. The most plausible explanation for the beneficial effects observed in patients with COPD treated with NAC lies in the mucolytic and antioxidant effects of this drug. Modulation of bronchial inflammation by NAC may further account for these favorable clinical results. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. The Rapid FEV1 Decline in Chronic Obstructive Pulmonary Disease Is Associated with Predominant Emphysema: A Longitudinal Study.
- Author
-
Cerveri, Isa, Corsico, Angelo G., Grosso, Amelia, Albicini, Federica, Ronzoni, Vanessa, Tripon, Bianca, Imberti, Federica, Galasso, Thomas, Klersy, Catherine, Luisetti, Maurizio, and Pistolesi, Massimo
- Subjects
- *
OBSTRUCTIVE lung diseases , *LONGITUDINAL method , *PULMONARY function tests , *EARLY medical intervention , *SMOKING , *HEALTH - Abstract
Background: Early identification of patients with COPD and prone to more rapid decline in lung function is of particular interest from both a prognostic and therapeutic point of view. The aim of this study was to identify the clinical, functional and imaging characteristics associated with the rapid FEV1 decline in COPD. Methods: Between 2001 and 2005, 131 outpatients with moderate COPD in stable condition under maximum inhaled therapy underwent clinical interview, pulmonary function tests and HRCT imaging of the chest and were followed for at least 3 years. Results: Twenty-six percent of patients had emphysema detected visually using HRCT. The FEV1 decline was 42 ± 66 mL/y in the total sample, 88 ± 76 mL/y among rapid decliners and 6 ± 54 mL/y among the other patients. In the univariable analysis, the decline of FEV1 was positively associated with pack-years (p < 0.05), emphysema at HRCT (p < 0.001), RV (p < 0.05), FRC (p < 0.05), FEV1 (p < 0.01) at baseline and with number of hospitalizations per year (p < 0.05) during the follow-up. Using multivariable analysis, the presence of emphysema proved to be an independent prognostic factor of rapid decline (p = 0.001). When emphysema was replaced by RV, the model still remained significant. Conclusions: The rapid decline in lung function may be identified by the presence of emphysema at HRCT or increased RV in patients with a long smoking history. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. SANI Clinical Remission definition: a useful tool in Severe Asthma management.
- Author
-
Canonica, Giorgio Walter, Bagnasco, Diego, Bondi, Benedetta, Varricchi, Gilda, Paoletti, Giovanni, Blasi, Francesco, Heffler, Enrico, Paggiaro, Pierluigi, Braido, Fulvio, Brussino, Luisa, Calabrese, Cecilia, Camiciottoli, Gianna, ElisianaCarpagnano, Giovanna, Centanni, Stefano, Guido Corsico, Angelo, Teresa Costantino, Maria, Crimi, Claudia, D’Adda, Alice, D’Alò, Simona, and D’Amato, Maria
- Subjects
- *
DISEASE remission , *ASTHMATICS , *ASTHMA , *PREVENTIVE medicine , *DEFINITIONS - Abstract
In the field of severe asthma, the concept of disease control has recently been integrated by the one of clinical remission. With this new concept, we move on to analyze the efficacy of therapy on multiple parameters simultaneously, starting with the mandatory discontinuation of the systemic glucocorticoids, to which is added the effect on exacerbations, respiratory function, and symptoms control. The Italian severe asthma registry SANI (Severe Asthma Network Italy) drafted criteria for the definition of disease remission, allowing patients to be classified into two groups, partial and complete remission. The greater dynamism of the definition, provided by SANI, allows us to hypothesize its practical use, concerning therapy management of severe asthma patients, starting from the level of remission, with the aim to facilitate the clinical decision on replacement, continuation or modulation of patients’ therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.